Format

Send to

Choose Destination
Int Ophthalmol. 2018 Apr;38(2):781-785. doi: 10.1007/s10792-017-0502-x. Epub 2017 Mar 30.

Bevacizumab for treatment of choroidal neovascularization secondary to candida chorioretinitis.

Author information

1
Bristol Eye Hospital, University Hospitals Bristol NHS Foundation Trust, Lower Maudlin Street, Bristol, BS1 2LX, UK.
2
Bristol Eye Hospital, University Hospitals Bristol NHS Foundation Trust, Lower Maudlin Street, Bristol, BS1 2LX, UK. carregnito@gmail.com.
3
School of Clinical Sciences, Faculty of Medicine and Dentistry, University of Bristol, Bristol, UK.
4
National Institute for Health Research Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK.

Abstract

PURPOSE:

To report a case of juxtafoveal choroidal neovascularization in a patient with candida chorioretinitis successfully treated with intravitreal bevacizumab.

METHODS:

Case report.

RESULTS:

A 45-year-old woman previously treated for candida chorioretinitis was presented with reduced vision in the left eye. The patient was investigated with ophthalmoscopy, fluorescein angiography, and optical coherence tomography (OCT). Following initial treatment, fundus examination, fluorescein angiography, and OCT of the right eye revealed a secondary juxtafoveal classic choroidal neovascularization. Following a single intravitreal injection of bevacizumab, the patient had excellent visual recovery, with absence of subretinal or intraretinal fluid in the OCT.

CONCLUSIONS:

Bevacizumab was effective in treatment of choroidal neovascularization associated with candida chorioretinitis.

KEYWORDS:

Bevacizumab; Candida; Chorioretinitis; Choroidal neovascular membrane

PMID:
28361379
DOI:
10.1007/s10792-017-0502-x
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center